0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Association Between Leukemia and Topical Use of Pimecrolimus

Yik Weng Yew, MBBS, MPH1; Hong Liang Tey, MBBS, FRCP(Edin)1
[+] Author Affiliations
1National Skin Centre, Singapore
JAMA Dermatol. 2015;151(12):1390-1391. doi:10.1001/jamadermatol.2015.3445.
Text Size: A A A
Published online

Extract

To the Editor We read with interest the observational cohort study by Margolis and colleagues1 that evaluated the risk of cancer among patients in the Pediatric Eczema Elective Registry who were exposed to pimecrolimus. The authors reported that the overall incidence rates of all cancers were not significantly higher than expected rates based on age-standardized rates from the Surveillance, Epidemiology, and End Results database. While it is certainly heartening to note these reassuring results, we are concerned about the age-specified incidence rate of leukemias among the age group 0 to 4 years in this study. There were 2 cases of acute lymphoblastic leukemia (ALL) in 2 African American children aged 0 to 4 years. Given a follow-up duration of 2585.10 person-years, the rate of leukemia would be 77.4 per 100 000 person-years (calculated as 2 cases per 2585.10, times 100 000). This is significantly higher than the expected rates of leukemia (7.9 per 100 000 person years). Notably, ALL is the most common pediatric cancer, with a peak incidence at age 2 to 5 years; therefore, evaluating the subgroup incidence rate ratio among children aged 0 to 4 years would be relevant.

Topics

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

December 1, 2015
David J. Margolis, MD, PhD; Katrina Abuabara, MD, MA; Ole J. Hoffstad, MS; Joy Wan, MD; Denise Raimondo, MSEd; Warren B. Bilker, PhD
1Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia2Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia
2Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia
1Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia
3Valeant Pharmaceuticals International, Bridgewater, New Jersey
JAMA Dermatol. 2015;151(12):1391-1392. doi:10.1001/jamadermatol.2015.3492.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

318 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();